Biosciences Division, SRI International, Menlo Park, California, USA.
Chirality. 2012 Oct;24(10):796-803. doi: 10.1002/chir.22072. Epub 2012 Jun 29.
The presystemic sulfate conjugation of the stereoisomers of 4'-methoxyfenoterol, (R,R')-MF, (S,S')-MF, (R,S')-MF, and (S,R')-MF, was investigated using commercially available human intestinal S9 fractions, a mixture of sulfotransferase (SULT) enzymes. The results indicate that the sulfation was stereospecific and that an S-configuration at the β-OH carbon of the MF molecule enhanced the maximal formation rates with (S,R')-MF (S,S')-MF (R,S')-MF ≈ (R,R')-MF, and competition studies demonstrated that (S,R')-MF is an effective inhibitor of (R,R')-MF sulfation (IC(50) = 60 μM). In addition, the results from a cDNA-expressed human SULT isoform screen indicated that SULT1A1, SULT1A3, and SULT1E1 can mediate the sulfation of all four MF stereoisomers. Previously published molecular models of SULT1A3 and SULT1A1 were used in docking simulations of the MF stereoisomers using Molegro Virtual Docker. The models of the MF-SULT1A3 and MF-SULT1A1 complexes indicate that each of the two chiral centers of MF molecule plays a role in the observed relative stabilities. The observed stereoselectivity is the result of multiple hydrogen bonding interactions and induced conformational changes within the substrate-enzyme complex. In conclusion, the results suggest that a formulation developed from a mixture of (R,R')-MF and (S,R')-MF may increase the oral bioavailability of (R,R')-MF.
研究了 4'-甲氧基非诺特罗((R,R')-MF、(S,S')-MF、(R,S')-MF 和(S,R')-MF)立体异构体在人肠 S9 片段(混合磺基转移酶(SULT)酶)中的前体硫酸盐结合。结果表明,磺化是立体特异性的,MF 分子β-OH 碳上的 S 构型增强了最大形成速率,(S,R')-MF>(S,S')-MF>(R,S')-MF>(R,R')-MF,竞争研究表明(S,R')-MF 是(R,R')-MF 磺化的有效抑制剂(IC50 = 60 μM)。此外,cDNA 表达的人 SULT 同工酶筛选结果表明,SULT1A1、SULT1A3 和 SULT1E1 可以介导所有四种 MF 立体异构体的磺化。先前发表的 SULT1A3 和 SULT1A1 分子模型用于使用 Molegro Virtual Docker 对 MF 立体异构体进行对接模拟。MF-SULT1A3 和 MF-SULT1A1 复合物模型表明,MF 分子的两个手性中心都在观察到的相对稳定性中发挥作用。观察到的立体选择性是由于在底物-酶复合物中存在多个氢键相互作用和诱导的构象变化。总之,结果表明,由(R,R')-MF 和(S,R')-MF 混合物开发的制剂可能会提高(R,R')-MF 的口服生物利用度。